82 results found. Viewing page 1 of 9. Go to page 1 2  . . . 8 9   Next

    GI Pathologists at Inform Diagnostics Publish Noteworthy Articles in Major Journals

    IRVING, Texas, May 14, 2018 — GI pathologists at Inform Diagnostics, formerly Miraca Life Sciences, continue to publish noteworthy articles in respected peer-reviewed medical journals. One recent article challenges current clinical assumptions about gastrointestinal polyps. Published in American Journal of Gastroenterology, “Lesions of All Types Exist in Colon Polyps of All ...

    Continue Reading

    Inform Diagnostics’ Previous Owner Miraca Holdings Announces Agreement in Principle with DOJ

    IRVING, Texas, May 2, 2018 — The previous owner of Inform Diagnostics, Miraca Holdings (MHD), announced today that its former subsidiary Miraca Life Sciences (now Inform Diagnostics) has reached an agreement in principle with the Department of Justice to enter into a civil settlement for $63.5 million related to an investigation that began in 2014. According to Miraca Holdings’ press ...

    Continue Reading

    Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

    MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that ...

    Continue Reading

    Renflexis™ Is Commercially Available from Inform Diagnostics

    IRVING, Texas, January 19, 2018 — Inform Diagnostics, formerly Inform Diagnostics Life Sciences, announced today that therapeutic drug monitoring is commercially available for Renflexis (infliximab-abda), a biosimilar of Remicade® (infliximab). Since launching the InformTx™ therapeutic drug monitoring (TDM) services in June 2016, the company has expanded its TDM testing to now ...

    Continue Reading

    Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

    IRVING, Texas, January 8, 2018 — Inform Diagnostics Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic ...

    Continue Reading

    Avista Capital Partners Completes Acquisition of Miraca Life Sciences

    IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Inform Diagnostics Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc. Continue reading the press release at the Avista website.

    Continue Reading

    Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

    IRVING, Texas, October 16, 2017 — Inform Diagnostics Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early ...

    Continue Reading

    Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

    MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that ...

    Continue Reading

    Avista Capital Partners to Acquire Miraca Life Sciences

    IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading ...

    Continue Reading

    Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

    Pathologists at Inform Diagnostics contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Inform Diagnostics participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Inform Diagnostics, participation in the Philips ...

    Continue Reading
82 results found. Viewing page 1 of 9. Go to page 1 2  . . . 8 9   Next